{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "IMRX",
  "name": "Immuneering Corporation",
  "url": "https://orbyd.app/dossiers/IMRX/",
  "json_url": "https://orbyd.app/dossiers/IMRX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Busted-catalyst pancreatic biotech: atebimetinib's 17.3-mo single-arm 1L OS is real, but the Phase 3 binary is mid-2028 and the tape keeps fading post-ASCO ($5.11→$4.32 in two weeks) even as targets climb to $18–$30. Cheap value-optionality (~$80M EV vs $198.6M cash) with no dated OS catalyst for ~2 years — a base-building watch, not fresh momentum.",
  "invalidation_trigger": "A weekly close below $3.90 undercuts the post-ASCO base and confirms the market de-rating atebimetinib's single-arm OS toward the $2.90 52-week low; a competing MEK/MAPK Phase 3 miss or a dilutive raise into the Aug 12 print compounds the break.",
  "catalyst_date": "2026-08-12",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology",
    "m-and-a-special-situations"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "CFO Andrew Gengos effective Jul 16 2026. Q2 2026 print est. ~mid-Aug (Q1 was May 15 2026).",
    "NSCLC optionality: atebimetinib + Regeneron cemiplimab Phase 2 dosing 2H 2026, preclinical Q4 2026, prelim data late 2027.",
    "Price $4.32 (Jul 24 2026); 52-wk $2.90-$10.08. Continued post-ASCO drift $5.11 (Jul 10)->~$4.48 (Jul 21)->$4.32 (Jul 24) while targets rose — price/coverage disconnect.",
    "Cash $198.6M (Mar 31 2026), runway into 2029; Q1 burn ~$15.3M (R&D $10.6M, G&A $4.7M; net loss $13.5M / $0.21). EV ~$80M vs $279.49M cap (64.70M sh).",
    "Lead asset atebimetinib (oral Deep Cyclic MEK inhibitor); Phase 2a 1L pancreatic 17.3-mo median OS, 64% 12-mo OS (55 pts, ASCO Jun 1 2026) vs ~35% historical GnP — single-arm vs historical control; curve matured 86% (9mo)->64% (12mo).",
    "Coverage building: Cantor Overweight (Jul 8), Needham Buy PT $11->$18 (Jul 20), Oppenheimer Outperform $30; 6-analyst avg ~$17 Strong Buy.",
    "Q2 2026 print confirmed Aug 12 2026 — cash/burn/enrollment, no OS data; watch dilution/ATM language. Avoid fresh entries into the print. CFO Andrew Gengos effective Jul 16 2026.",
    "Cancer Research publication Jul 21 2026 characterized atebimetinib mechanism + broad preclinical activity."
  ],
  "body_markdown": "## Current Thesis\nImmuneering is a busted-catalyst clinical-stage oncology name. Its lead asset, atebimetinib (oral once-daily \"Deep Cyclic\" MEK inhibitor), posted a 17.3-month median overall survival in first-line metastatic pancreatic cancer at ASCO on June 1, 2026 — roughly 5–6 months beyond the ~11–12 month standard-of-care benchmark — yet the tape has faded continuously since. Shares slid from $5.11 (July 10) to $4.32 (July 24) while sell-side targets ran the other way. The pivotal Phase 3 overall-survival readout that confirms or kills the story is mid-2028, leaving a ~2-year window with no dated survival catalyst. What is left near term is a coverage-and-cash story on a small float, and an enterprise value near $80M against $198.6M of cash — value optionality on a base that has not yet stopped bleeding.\n\n## Bull Case\n- Phase 2a atebimetinib + modified gemcitabine/nab-paclitaxel delivered 17.3-month median OS and 64% OS at 12 months across 55 first-line metastatic pancreatic patients (ASCO, June 1, 2026), versus ~35% historical 12-month survival for GnP alone — an outlier in an indication where most agents fail to move the curve.\n- Needham reiterated Buy and lifted its target from $11 to $18 on July 20, 2026; Cantor Fitzgerald initiated Overweight July 8; Oppenheimer carries Outperform at $30; the six-analyst consensus is Strong Buy near $17 (~4x the July 24 price). Coverage is early and expanding, not saturated.\n- A July 21, 2026 Cancer Research publication characterized atebimetinib's differentiated MEK mechanism and broad preclinical activity — incremental scientific validation that could widen the label beyond pancreatic.\n- Pivotal Phase 3 MAPKeeper 301 dosed its first patient June 11, 2026 (510 patients, randomized open-label, atebimetinib + mGnP vs GnP), with FDA and EMA alignment already secured — the regulatory path is defined.\n- $198.6M cash (March 31, 2026) funds operations into 2029, through the Phase 3 topline, on ~$15.3M quarterly burn. Against a $279.49M market cap, enterprise value is roughly $80M — cheaper than a month ago, as the cap compressed while the cash held.\n- Small structure (64.70M shares) leaves the name squeeze-prone on any positive flow or M&A speculation.\n- NSCLC optionality: atebimetinib + Regeneron's cemiplimab (Libtayo) Phase 2 begins dosing 2H 2026, with preclinical support expected Q4 2026 and preliminary data late 2027.\n\n## Bear Case\n- The 17.3-month OS is a single-arm result measured against historical control rather than a randomized comparator. Pancreatic cross-trial comparisons have repeatedly failed to replicate in controlled Phase 3, and the market discounted exactly this on June 1, 2026 by selling the headline survival print.\n- The real binary — randomized Phase 3 OS — is ~2 years out (mid-2028). A momentum book has no dated survival catalyst to ride between now and then.\n- Price structure is broken and deteriorating: $4.32 on July 24 is ~57% below the $10.08 52-week high and down ~15% in the two weeks since ASCO enthusiasm faded, even as three firms raised or reiterated bullish targets. When price ignores rising targets, the marginal buyer is absent.\n- The survival curve matured downward from 86% at 9 months to 64% at 12 months. Directionally expected as follow-up lengthens, but it keeps the final randomized number unknowable and hands sellers a talking point.\n- A global 510-patient Phase 3 pressures the balance sheet; even with runway into 2029, an opportunistic ATM or secondary on any strength is live dilution risk — a real overhang for a name this small.\n- Q2 2026 earnings (August 12) refresh burn and cash but carry no OS data — a print that can disappoint on dilution language with no offsetting catalyst.\n\n## Setup & Price Structure\n- Last print $4.32 (July 24, 2026), inside a 52-week range of $2.90–$10.08. The name sits ~49% above its low and ~57% below its high — a broken-down structure with no sign the base has turned.\n- The post-ASCO slide is orderly and persistent: $5.11 (July 10) → ~$4.48 (July 21) → $4.32 (July 24). Lower highs, lower closes, no reclaim of the pre-ASCO shelf.\n- The $3.90–$4.00 zone is the post-ASCO base; a weekly close beneath it opens air toward the $2.90 52-week low.\n- Market cap $279.49M on 64.70M shares; enterprise value ~$80M net of $198.6M cash. The cheapness is real but has been cheap-and-falling for two weeks — a value screen the tape keeps ignoring.\n- Analyst-target dispersion is wide ($17 consensus, $18 Needham, $30 Oppenheimer) against a $4.32 tape — the gap reflects a story the market refuses to pay up for until randomized data arrives.\n- For momentum capital this is a stand-aside-until-it-bases name: no accelerating tape, no near-term survival catalyst, continued distribution.\n\n## Catalyst Calendar (next 30 days)\n- **August 12, 2026 — Q2 2026 earnings** (confirmed date). Cash, burn, and Phase 3 enrollment cadence update; no OS data. Watch for dilution / ATM commentary and any change to the \"into 2029\" runway guide.\n- **Ongoing — MAPKeeper 301 enrollment progress**. Any interim enrollment or site-expansion disclosure into the print would signal execution pace.\n- **2H 2026 (undated) — NSCLC Phase 2 dosing start** (atebimetinib + cemiplimab); a dosing-initiation release could land in this window but is not date-confirmed.\n- No overall-survival catalyst is scheduled inside 30 days; the pivotal OS topline remains mid-2028.\n\n## What Would Change Our Mind\n- **Constructive flip:** a weekly close back above ~$5.20 that reclaims the pre-ASCO shelf on expanding volume, ideally alongside an M&A rumor or a dated pipeline catalyst pulled forward — that turns the coverage-and-cash story into a tradable base breakout.\n- **Confirmation of the break:** a weekly close below $3.90 undercuts the post-ASCO base and signals the market de-rating the single-arm OS toward the $2.90 low.\n- **Thesis kill:** a competing MEK/MAPK-pathway Phase 3 miss in pancreatic or colorectal, a dilutive raise priced into weakness, or MAPKeeper 301 enrollment stumbles that push the mid-2028 topline right.\n- **Theme context:** the broader oncology-immunology theme flipping to a saturated, risk-off stance would strip the small-cap-biotech bid entirely and accelerate the drift.\n\n## Correlation Notes\n- Trades with small-cap clinical biotech risk appetite (XBI) far more than with any pancreatic-cancer peer; on risk-off tape, sub-$300M-cap single-asset names gap regardless of company-specific news.\n- Single-asset binary: the overwhelming majority of equity value keys off atebimetinib's Phase 3 OS. There is no commercial revenue and no second de-risked asset to cushion a pipeline setback.\n- Read-through risk from other MEK/RAS/MAPK-pathway programs (pipeline data from larger oncology developers) can move the stock on peer news alone, independent of Immuneering's own timeline.\n- Rate-sensitive like most pre-revenue biotech: a higher-for-longer regime compresses long-duration clinical-stage valuations and keeps a lid on the multiple until randomized data forces a re-rate.",
  "first_seen": "2026-07-10",
  "last_analyzed": "2026-07-26T12:23:28+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}